Loading stocks --

AGP & GLAXO 3QCY26 Earnings Preview: JS Research expectations for pharma sector

JS Global Capital Limited
Stock ImpactPositive

AGP & GLAXO: 3QCY26 Earnings Preview

JS Global - 29 October 2026

Report Overview

JS Research has released its 3QCY26 earnings expectations for Pakistan Pharma sector stocks: GlaxoSmithKline Pakistan Limited (GLAXO) and AGP Limited (AGP). While GLAXO is expected to post strong YoY growth, AGP sales remain under pressure.

GlaxoSmithKline Pakistan Limited (GLAXO)

Bloomberg Code: GLAXO PA
Target Price: Rs510
Market Price: Rs315.00
Market Cap: Rs100bn (US$362mn)

JS Research expects GLAXO to post a 22% YoY growth in 3QCY26 earnings to Rs2,485mn, or Rs7.80/share. Revenue growth is anticipated to be broad-based, driven by key brands including Amoxil, Calpol, and Dermovate, alongside strong volumetric growth in the Shingrix vaccine.

AGP Limited (AGP)

Bloomberg Code: AGP PA
Target Price: Rs275
Market Price: Rs151.27
Market Cap: Rs42bn (US$153mn)

AGP is expected to report a 28% YoY decline in consolidated EPS to Rs2.67 for 3QCY26, with PAT declining to Rs747mn. The underperformance is attributed to weaker antibiotic sales and negligible exports following trade suspension with Afghanistan.

Key Financial Estimates

CompanyPeriodNet Sales (Rs mn)PAT (Rs mn)EPS (Rs)
GLAXO3QCY26E17,3262,4857.80
AGP3QCY26E7,0007472.67

Risks

Company-specific risks, competition risks, regulatory changes, macroeconomic volatility, and commodity price fluctuations.